XRK3F2
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 558760

CAS#: NONE

Description: XRK3F2 is an inhibitor of signaling via the ZZ domain of p62 (Sequestosome 1), blocking tumor necrosis factor (TNF) and multiple myeloma‐induced Gfi1 upregulation, resulting in decreased binding and recruitment of HDAC1 to the RUNX2 promoter in pre‐OBs.


Price and Availability

Size
Price

5mg
USD 280
Size
Price

10mg
USD 440
Size
Price

50mg
USD 970

XRK3F2, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data, and MSDS documents are available in one week after order is received.


Chemical Structure

No image available

Theoretical Analysis

MedKoo Cat#: 558760
Name: XRK3F2
CAS#: NONE
Chemical Formula: C23H24ClF2NO3
Exact Mass:
Molecular Weight: 435.8958
Elemental Analysis: C, 63.38; H, 5.55; Cl, 8.13; F, 8.72; N, 3.21; O, 11.01


Synonym: XRK-3F2; XRK 3F2; XRK3F2

IUPAC/Chemical Name: 2-[[3,4-Bis[(4-fluorophenyl)methoxy]phenyl]methylamino]ethanol hydrochloride

InChi Key: XBSQIUHKVROJDN-UHFFFAOYSA-N

InChi Code: InChI=1S/C23H23F2NO3.ClH/c1-26(12-13-27)21-10-11-22(28-15-17-2-6-19(24)7-3-17)23(14-21)29-16-18-4-8-20(25)9-5-18;/h2-11,14,27H,12-13,15-16H2,1H3;1H

SMILES Code: CN(CCO)C1=CC=C(OCC2=CC=C(F)C=C2)C(OCC3=CC=C(F)C=C3)=C1.[H]Cl


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>3 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
2934.99.90.01


References

1: Adamik J, Silbermann R, Marino S, Sun Q, Anderson JL, Zhou D, Xie XQ, Roodman GD, Galson DL. XRK3F2 Inhibition of p62-ZZ Domain Signaling Rescues Myeloma-Induced GFI1-Driven Epigenetic Repression of the Runx2 Gene in Pre-osteoblasts to Overcome Differentiation Suppression. Front Endocrinol (Lausanne). 2018 Jun 29;9:344. doi: 10.3389/fendo.2018.00344. eCollection 2018. PubMed PMID: 30008697; PubMed Central PMCID: PMC6033965.

2: Teramachi J, Silbermann R, Yang P, Zhao W, Mohammad KS, Guo J, Anderson JL, Zhou D, Feng R, Myint KZ, Maertz N, Beumer JH, Eiseman JL, Windle JJ, Xie XQ, Roodman GD, Kurihara N. Blocking the ZZ domain of sequestosome1/p62 suppresses myeloma growth and osteoclast formation in vitro and induces dramatic bone formation in myeloma-bearing bones in vivo. Leukemia. 2016 Feb;30(2):390-8. doi: 10.1038/leu.2015.229. Epub 2015 Aug 19. PubMed PMID: 26286116; PubMed Central PMCID: PMC4740189.